After thriving on the market for more than a decade as the only treatment for Dupuytrens contracture and Peyronie’s disease, Keenova Therapeutics’ Xiaflex has
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
In the past two weeks, CARsgen Therapeutics won the world's first regulatory approval for a solid tumor CAR-T, a…
Reporting a new miss in one indication, Karyopharm Therapeutics is plowing ahead with plans to advance its XPO1 inhibitor Xpovio…
Takeda's first-in-class orexin treatment won an FDA nod in narcolepsy. Daiichi Sankyo faced investor pushback after admitting to…
In 2017, a little-known company called Nanjing Legend Biotech walked into the ASCO annual meeting at the 11th hour, dropped a…
Keenova Reports Second Quarter 2026 Financial Results
Keenova Announces Positive Phase 3 Results in Clinical Trial of XIAFLEX® (collagenase clostridium histolyticum) for Treating…
